A Phase 2/3, open-label, multicenter, multi-cohort, 2-part study evaluating pharmacokinetics (PK), safety, and efficacy of once-daily cobicistat-boosted darunavir (DRV/co) administered with a backgrou
02/10/2014 - 02/03/2016 (PI)Gilead Sciences, Inc.
A Phase 2/3 Multicenter, Open-label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered with a Background Regimen (BR)
02/04/2014 - 01/31/2016 (PI)Gilead Sciences, Inc.
A phase 2/3 open-label study of pharmacokinetics, safety and antiviral activity of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxii fumarte single table regimen (STR) in HIV-1 infected a
10/01/2012 - 09/30/2014 (PI)Gilead Sciences, Inc.
An open label prospective, pharmacokinetic/pharmacodynamic and safety evaluation of intravenous oseltamivir, Tamiflu, in the treatment of children 1 to 12 years of age with confirmed influenza
04/30/2010 - 09/30/2013 (PI)Roche Pharmaceuticals
An open label prospective, pharmacokinetic/pharmacodynamic and safety evaluation of intravenous oseltamivir (Tamiflu) in the treatment of infants less than one year of age with influenza infecti
08/01/2010 - 08/15/2013 (PI)F. Hoffmann-La Roche, Ltd.
A Pivotal Phase 3 Study of MEDI-524 (Numax), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High-Risk Children
09/14/2004 - 12/31/2009 (PI)MedImmune, Inc.
A Prospective, Non-Interventional Study to Evaluate the Incidence of Hospitalizations and Medically-Attended Lower Respiratory Tract Infection (MALRI) in Premature Infants 32 to 35 Weeks Gestational Age Who are Not Recommended to Receive Prophylaxis for R
12/22/2006 - 06/30/2007 (PI)MedImmune, Inc.
RSV Outbreaks in the Boston Medical Center NICU: The Role of Palibizumab in Prevention
10/01/2002 - 09/30/2003 (PI)MedImmune, Inc.
Ryan White HIV/AIDS Program Part D Continuation Funding for Services to Women, Infants, Children and Youth (WICY) in the Boston Eligible Metropolitan Area (EMA)
08/01/2022 - 07/31/2024 (PI)HIV/AIDS Bureau/HRSA/DHHS
A multi- site observational study to assess safety and effectiveness of prenatal exposure to…
05/18/2020 - 12/31/2023 (PI)ViiV Healthcare
An Epidemiologic Study of Pregnant Women and Their Newborn Infants to Describe Immune Status…
10/12/2015 - 03/15/2021 (PI)Pfizer, Inc Pfizer, Inc
PlusCare: Mobile platform to increase linkage to care in adolescents living with HIV/AIDS
05/01/2018 - 09/30/2020 (PI)Dimagi Inc. National Institute o5R44MH117956-03
The SENTINEL 1 Study
12/02/2014 - 04/30/2017 (PI)Astrazeneca Pharmaceuticals
Conducting CASG 117 - A Pharmacokinetic / Pharmcodynamic and Safety Evaluation of Investigational In
03/01/2010 - 09/30/2013 (PI)Social & Scientific Systems Inc. NIH-NIAID
Combination Antiviral Focus Group
11/01/2009 - 09/30/2013 (PI)Social & Scientific Systems Inc. NIH-NIAID
AIDSTAR - One Program
08/01/2010 - 12/31/2012 (PI)John Snow, Inc. USAID
Title IV Case findings Early Intervention
10/01/2001 - 08/31/2012 (PI)Justice Resource Institute DHHS
MassCARE (Community AIDS Resource Enhancement)
10/01/2001 - 06/30/2011 (PI)DPH HRSA
Showing 10 of 22 results.
Show All Results